Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models

Discrete and Continuous Dynamical Systems - Series B

Volumn 12, Issue 2, 2009, Pages 415-438

  Ledzewicz, Urszula ^a   Munden, James ^b   Scháttler, Heinz ^c  

^a SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

Anti angiogenesis; Cancer treatment; Maximum principle; Optimal control; Regular synthesis; Singular control

Indexed keywords

EID: 70349932156     PISSN: 15313492     EISSN: None     Source Type: Journal    
DOI: 10.3934/dcdsb.2009.12.415     Document Type: Conference Paper

References (44)

1. A. Anderson and M. Chaplain, Continuous and discrete mathematical models of tumorinduced angiogenesis, Bull. Math. Biol., 60 (1998), 857-899.
2. L. Arakelyan, V. Vainstain and Z. Agur, A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumour growth, Angiogenesis, 5 (2002), 203-214.
3. B. Bonnard and M. Chyba, "Singular Trajectories and Their Role in Control Theory, " Springer Verlag, Series: Mathematics and Applications, 40, 2003.
4. B. Bonnard and J. de Morant, Toward a geometric theory in the time-minimal control of chemical batch reactors, SIAM J. Control Optim., 33 (1995), 1279-1311.
5. T. Boehm, J. Folkman, T. Browder and M. S. O'Reilly, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature, 390 (1997), 404-407.
6. A. Bressan and B. Piccoli, "Introduction to the Mathematical Theory of Control, " American Institute of Mathematical Sciences, 2007.
7. A. E. Bryson and Y. C. Ho, "Applied Optimal Control, " Hemisphere Publishing, 1975.
8. F. Castiglione and B. Piccoli, Optimal control in a model of dendritic cell transfection cancer immunotherapy, Bulletin of Mathematical Biology, 68, (2006), 255-274
9. L. G. de Pillis and A. Radunskaya, A mathematical tumor model with immune resistance and drug therapy: An optimal control approach, J. of Theoretical Medicine, 3, (2001), 79-100.
10. A. d'Onofrio, A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences, Physica D, 208, (2005), 220-235.
11. A. d'Onofrio, Rapidly acting antitumoral anti-angiogenic therapies, Physical Review E, 76 (3), Art. No. 031920, 2007.
12. A. d'Onofrio and A. Gandolfi, Tumour eradication by antiangiogenic therapy: Analysis and extensions of the model by Hahnfeldt et al. (1999), Math. Biosci., 191, (2004), 159-184.
13. A. D'Onofrio and A. Gandolfi, A family of models of angiogenesis and antiangiogenesis anti-cancer therapy, Mathematical Medicine and Biology, 26 (2009), 63-95, doi:10.1093/imammb/dqn024.
14. S. Davis and G. D. Yancopoulos, The anbgiopoietins: Yin and Yang in angiogenesis, Curr. Top. Microbiol. Immunol., 237 (1999), 173-185.
15. A. Ergun, K. Camphausen and L. M. Wein, Optimal scheduling of radiotherapy and angiogenic inhibitors, Bull. of Math. Biology, 65 (2003), 407-424.
16. K. R. Fister and J. C. Panetta, Optimal control applied to cell-cycle-specific cancer chemotherapy, SIAM J. Appl. Math., 60 (2000), 1059-1072.
17. J. Folkman, Antiangiogenesis: New concept for therapy of solid tumors, Ann. Surg., 175 (1972), 409-416.
18. J. Folkman, Angiogenesis inhibitors generated by tumors, Mol. Med., 1 (1995), 120-122.
19. J. Folkman and M. Klagsburn, Angiogenic factors, Science, 235 (1987), 442-447.
20. U. Forys, Y. Keifetz and Y. Kogan, Critical-point analysis for three-variable cancer angiogenesis models, Mathematical Biosciences and Engineering, 2 (2005), 511-525.
21. P. Hahnfeldt, D. Panigrahy, J. Folkman and L. Hlatky, Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Research, 59 (1999), 4770-4775.
22. R. S. Kerbel, A cancer therapy resistant to resistance, Nature, 390 (1997), 335-336.
23. D. Kirschner, S. Lenhart and S. Serbin, Optimal control of chemotherapy of HIV, J. Math. Biol., 35 (1997), 775-792.
24. M. Klagsburn and S. Soker, VEGF/VPF: The angiogenesis factor found? Curr. Biol., 3 (1993), 699-702.
25. U. Ledzewicz and H. Schãttler, Optimal bang-bang controls for a 2-compartment model in cancer chemotherapy, J. of Optimization Theory and Applications - JOTA, 114 (2002), 609-637. (Pubitemid 39583314)
26. U. Ledzewicz and H. Schãttler, The influence of PK/PD on the structure of optimal control in cancer chemotherapy models, Mathematical Biosciences and Engineering (MBE), 2, (2005), 561-578.
27. U. Ledzewicz and H. Schãttler, A synthesis of optimal controls for a model of tumor growth under angiogenic inhibitors, Proceedings of the 44th IEEE Conference on Decision and Control, Sevilla, Spain, December 2005, 934-939.
28. U. Ledzewicz and H. Schãttler, Anti-angiogenic therapy in cancer treatment as an optimal control problem, SIAM J. on Control and Optimization, 46 (2007), 1052-1079.
29. U. Ledzewicz and H. Schãttler, Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy, Mathematical Biosciences, 206 (2007), 320-342.
30. U. Ledzewicz and H. Schãttler, Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis, J. of Theoretical Biology, 252 (2008), 295-312.
31. U. Ledzewicz and H. Schãttler, Analysis of a mathematical model for tumor anti-angiogenesis, Optimal Control Appl. and Methods, 29 (2008), 41-57.
32. U. Ledzewicz and H. Schãttler, On the optimality of singular controls for a class of mathematical models for tumor anti-angiogenesis, Discrete and Continuous Dynamical Systems, Series B, 11 (2009), 691-715.
33. U. Ledzewicz, J. Marriott, H. Maurer and H. Schãttler, Realizable protocols for optimal administration of drugs in mathematical models for anti-angiogenic treatment, Mathematical Medicine and Biology, (2009), to appear.
34. R. Martin and K. L. Teo, "Optimal Control of Drug Administration in Cancer Chemotherapy, " World Scientific, Singapure, 1994.
35. H. Maurer, C. Bũskens, J.-H. Kim and Y. Kaja, Optimization techniques for the verification of second-order sufficient conditions for bang-bang controls, Optimal Control, Applications and Methods, 26 (2005), 129-156. (Pubitemid 40892084)
36. R. K. Sachs, L. R. Hlatky and P. Hahnfeldt, Simple ODE models of tumor growth and antiangiogenic or radiation treatment, Math. Comput. Mod., 33 (2001), 1297-1305.
37. H. Schãttler and M. Jankovic, A synthesis of time-optimal controls in the presence of saturated singular arcs, Forum Mathematicum, 5 (1993), 203-241.
38. G. Stefani, On sufficient optimality conditions for singular extremals, Proceedings of the 42nd IEEE Conference on Decision and Control (CDC), Maui, Hi, USA, December 2003, 2746-2749.
39. G. W. Swan, Role of optimal control in cancer chemotherapy, Math. Biosci., 101 (1990), 237-284.
40. A. Swierniak, Optimal treatment protocols in leukemia - modelling the proliferation cycle, Proceedings of the 12th IMACS World Congress, Paris, 4 (1988), 170-172.
41. A. Swierniak, U. Ledzewicz and H. Schãttler, Optimal control for a class of compartmental models in cancer chemotherapy, Int. J. Applied Mathematics and Computer Science, 13, (2003), 357-368.
42. A. Swierniak, A. Polanski and M. Kimmel, Optimal control problems arising in cell-cyclespecific cancer chemotherapy, Cell prolif., 29 (1996), 117-139.
43. A. Swierniak, G. Gala, A. Gandolfi and A. d'Onofrio, Optimization of angiogenic therapy as optimal control problem, Proceedings of the 4th IASTED Conference on Biomechanics, Acta Press, (Ed. M. Doblare), (2006), 56-60.
44. A. Swierniak, Direct and indirect control of cancer populations, Bulletin of the Polish Academy of Sciences, Technical Sciences, 56 (2008), 367-378.